

Ella Zomer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7178006/ella-zomer-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

1,022
citations

16
h-index

28
g-index

92
ext. papers

1,571
ext. citations

5
avg, IF

4.8
L-index

#	Paper	IF	Citations
85	Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia.. <i>Pharmacoeconomics</i> , 2022 , 1	4.4	0
84	Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system. <i>Leukemia Research</i> , 2021 , 112, 106748	2.7	0
83	Attainment of low-density lipoprotein cholesterol goals in statin treated patients: real-world evidence from Australia. <i>Current Problems in Cardiology</i> , 2021 , 101068	17.1	2
82	The Impact of Diabetes on Productivity in India. <i>Diabetes Care</i> , 2021 , 44, 2714-2722	14.6	0
81	The impact of coronary heart disease prevention on work productivity: a 10-year analysis. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 418-425	3.9	3
80	Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	3
79	Characterising experiences with acute myeloid leukaemia using an Instagram content analysis. <i>PLoS ONE</i> , 2021 , 16, e0250641	3.7	0
78	Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data. <i>Current Problems in Cardiology</i> , 2021 , 100880	17.1	2
77	Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia Between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY). <i>JCO Oncology Practice</i> , 2021 , 17, e1803-e1810	2.3	0
76	Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	3
75	The Health and Productivity Burden of Depression in South Korea. <i>Applied Health Economics and Health Policy</i> , 2021 , 19, 941-951	3.4	0
74	Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden. <i>Pharmacoeconomics</i> , 2021 , 39, 271-273	4.4	6
73	The Preventable Productivity Burden of Kidney Disease in Australia. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	1
72	Productivity burden of hypertension in Japan. <i>Hypertension Research</i> , 2021 , 44, 1524-1533	4.7	1
71	Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021 , 30, 105931	2.8	4
70	It doesn't stop at validation: patient reported outcome measures require ongoing and iterative development. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	
69	Cost-effectiveness of Radial Access Percutaneous Coronary Intervention in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2021 , 156, 44-51	3	1

68	Productivity Benefits of Preventing Type 2 Diabetes in Australia: A 10-Year Analysis. <i>Diabetes Care</i> , 2021 , 44, 715-721	14.6	0
67	Estimating the economic impacts of percutaneous coronary intervention in Australia: a registry-based cost burden study. <i>BMJ Open</i> , 2021 , 11, e053305	3	0
66	Natural Regression of Frailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. <i>Gerontologist, The</i> , 2020 , 60, e286-e298	5	10
65	Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020 , 22, 812-821	8.1	9
64	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. <i>Pharmacoeconomics</i> , 2020 , 38, 1095-1113	4.4	11
63	The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487319896648	3.9	13
62	Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling. <i>BMJ Open</i> , 2020 , 10, e041832	3	1
61	Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling. <i>BMJ Open</i> , 2020 , 10, e041832	3	1
60	An Economic Evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry Program (ANZACS-QI 28). <i>Heart Lung and Circulation</i> , 2020 , 29, 1046-1053	1.8	0
59	The Health and Productivity Burden of Migraines in Australia. <i>Headache</i> , 2020 , 60, 2291-2303	4.2	4
58	Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 772-783	4.9	9
57	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320938272	3.9	15
56	The economic impact of familial hypercholesterolemia on productivity. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 799-806.e3	4.9	3
55	Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis. <i>Systematic Reviews</i> , 2020 , 9, 171	3	6
54	Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2020 , 38, 1007-1020	4.4	8
53	The impact of diabetes on the productivity and economy of Bangladesh. <i>BMJ Global Health</i> , 2020 , 5,	6.6	10
52	Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. <i>BMJ Open</i> , 2020 , 10, e039221	3	5
51	The costs of epilepsy in Australia: A productivity-based analysis. <i>Neurology</i> , 2020 , 95, e3221-e3231	6.5	9

50	Impact of tobacco use on health and work productivity in Malaysia. <i>Tobacco Control</i> , 2020 , 29, 111-117	5.3	13
49	Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. <i>Heart Lung and Circulation</i> , 2020 , 29, 1310-1317	1.8	3
48	An economic evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry programme-subanalyses for Māori (ANZACS-QI 42). <i>New Zealand Medical Journal</i> , 2020 , 133, 16-32	0.8	
47	Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. <i>European Journal of Preventive Cardiology</i> , 2019 , 2047487319878953	3.9	7
46	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2019 , 285, 1-5	3.2	9
45	Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. <i>Pharmacoeconomics</i> , 2019 , 37, 1277-1286	4.4	6
44	The impact of diabetes on productivity in China. <i>Diabetologia</i> , 2019 , 62, 1195-1203	10.3	19
43	Productivity Burden of Hypertension in Australia. <i>Hypertension</i> , 2019 , 73, 777-784	8.5	30
42	The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. <i>BMC Musculoskeletal Disorders</i> , 2019 , 20, 90	2.8	102
41	Recent Patterns of Multimorbidity Among Older Adults in High-Income Countries. <i>Population Health Management</i> , 2019 , 22, 127-137	1.8	58
40	Productivity burden of smoking in Australia: a life table modelling study. <i>Tobacco Control</i> , 2019 , 28, 297-304	3.0	24
39	Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. <i>Vaccine</i> , 2019 , 37, 5009-5015	4.1	2
38	Global Incidence of Frailty and Pre frailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2019 , 2, e198398	10.4	119
37	Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome. <i>Cardiovascular Diagnosis and Therapy</i> , 2019 , 9, 250-261	2.6	11
36	Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. <i>Diabetes Research and Clinical Practice</i> , 2019 , 158, 107909	7.4	1
35	Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT. <i>Programme Grants for Applied Research</i> , 2019 , 7, 1-98	1.5	2
34	Economic evaluation of clinical quality registries: a systematic review. <i>BMJ Open</i> , 2019 , 9, e030984	3	4
33	Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 227-235	3.8	21

32	Predictors of statin use among older adults: A nationwide cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 156-162.e1	4.9	7
31	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 858-868	3.9	10
30	The Productivity Burden of Diabetes at a Population Level. <i>Diabetes Care</i> , 2018 , 41, 979-984	14.6	38
29	Patterns of statin use and long-term adherence and persistence among older adults with diabetes. <i>Journal of Diabetes</i> , 2018 , 10, 699-707	3.8	23
28	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged 65 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 798-805	6.4	30
27	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 813-819	6.4	48
26	Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. <i>American Journal of Hypertension</i> , 2018 , 31, 1156-1163	2.3	8
25	Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018 , 33, 527-534	2.5	8
24	Self-sampling kits to increase HIV testing among black Africans in the UK: the HAUS mixed-methods study. <i>Health Technology Assessment</i> , 2018 , 22, 1-158	4.4	10
23	Measures of Population Ageing in Australia from 1950 to 2050. <i>Journal of Population Ageing</i> , 2018 , 11, 367-385	1.2	12
22	Patterns of Medication Dispensation for Multiple Comorbidities among Older Adults in Australia. <i>Pharmacy (Basel, Switzerland)</i> , 2018 , 6,	2	2
21	Switching, Discontinuation, and Reinitiation of Statins Among Older Adults. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2675-2677	15.1	10
20	Effect of Comorbidity Assessed by the Charlson Comorbidity Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for Acute Stroke. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	26
19	Could low birth weight and preterm birth be associated with significant burden of hip osteoarthritis? A systematic review. <i>Arthritis Research and Therapy</i> , 2018 , 20, 121	5.7	8
18	A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 265-272	3.9	14
17	The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2018 , 267, 183-187	3.2	19
16	Cost of gastroenteritis in Australia: A healthcare perspective. <i>PLoS ONE</i> , 2018 , 13, e0195759	3.7	14
15	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. <i>International Journal of Cardiology</i> , 2018 , 270, 54-59	3.2	14

14	Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE). <i>BMJ Open</i> , 2017 , 7, e018181	3	9
13	Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 118-124	6.7	8
12	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017 , 6, e39	2	3
11	Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2016 , 17, 80	2.8	9
10	Can oral vitamin D prevent the cardiovascular diseases among migrants in Australia? Provider perspective using Markov modelling. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015 , 42, 596-601	3	3
9	Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 384-90	3.9	12
8	Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data. <i>International Journal of Cardiology</i> , 2014 , 175, 72-7	3.2	5
7	Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis. <i>American Journal of Cardiovascular Drugs</i> , 2013 , 13, 121-8	4	5
6	Outcomes and excess costs among patients with cardiovascular disease. <i>Heart Lung and Circulation</i> , 2013 , 22, 724-30	1.8	7
5	Overview of pharmacoeconomic modelling methods. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 944-50	3.8	26
4	Statins for people at low risk of cardiovascular disease. <i>Lancet, The</i> , 2012 , 380, 1817; author reply 1817-8	4.0	3
3	The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model. <i>BMJ, The</i> , 2012 , 344, e3657	5.9	30
2	Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the QldQ versus the QewQ Framingham equation. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 115-20		24
1	Urotensin II in chronic liver disease: in vivo effect on vascular tone. <i>Scandinavian Journal of Gastroenterology</i> , 2008 , 43, 103-9	2.4	6